These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38311374)

  • 21. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study.
    Geboers B; Gondoputro W; Thompson JE; Reesink DJ; van Riel LAMJG; Zhang D; Blazevski A; Doan P; Agrawal S; Matthews J; Haynes AM; Liu Z; Delprado W; Shnier R; de Reijke TM; Lawrentschuk N; Stijns PEF; Yaxley JW; Scheltema MJ; Stricker PD
    Eur Urol Focus; 2022 Nov; 8(6):1591-1598. PubMed ID: 35577751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.
    Marra G; Shah TT; D'Agate D; Marquis A; Calleris G; Lunelli L; Filippini C; Oderda M; Gatti M; Valerio M; Sanchez-Salas R; Bossi A; Gomez-Rivas J; Conte F; Deandreis D; Cussenot O; Ricardi U; Gontero P
    Front Surg; 2022; 9():900528. PubMed ID: 35747441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transperineal Laser Ablation for Focal Therapy of Localized Prostate Cancer: 12-Month Follow-up Outcomes from a Single Prospective Cohort Study.
    Iacovelli V; Carilli M; Bertolo R; Forte V; Vittori M; Filippi B; Di Giovanni G; Cipriani C; Petta F; Maiorino F; Signoretti M; Antonucci M; Guidotti A; Travaglia S; Caputo F; Manenti G; Bove P
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
    BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irreversible electroporation as a focal therapy for localized prostate cancer: A systematic review.
    Prabhakar P; Avudaiappan AP; Sandman M; Eldefrawy A; Caso J; Narayanan G; Manoharan M
    Indian J Urol; 2024; 40(1):6-16. PubMed ID: 38314081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results.
    Anttinen M; Mäkelä P; Viitala A; Nurminen P; Suomi V; Sainio T; Saunavaara J; Taimen P; Sequeiros RB; Boström PJ
    Eur Urol Open Sci; 2020 Dec; 22():79-87. PubMed ID: 34337481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.
    Giganti F; Stabile A; Giona S; Marenco J; Orczyk C; Moore CM; Allen C; Kirkham A; Emberton M; Punwani S
    Magn Reson Imaging; 2019 May; 58():143-147. PubMed ID: 30768957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.
    Valerio M; Stricker PD; Ahmed HU; Dickinson L; Ponsky L; Shnier R; Allen C; Emberton M
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):343-7. PubMed ID: 25179590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer.
    Lantz A; Nordlund P; Falagario U; Jäderling F; Özbek O; Clements M; Discacciati A; Grönberg H; Eklund M; Stricker P; Emberton M; Aly M; Nordström T
    Eur Urol Open Sci; 2023 May; 51():89-94. PubMed ID: 37091033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
    Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
    Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focal Irreversible Electroporation for Localized Prostate Cancer - Oncological and Safety Outcomes Using mpMRI and Transperineal Biopsy Follow-Up.
    Gielchinsky I; Lev-Cohain N
    Res Rep Urol; 2023; 15():27-35. PubMed ID: 36714797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Irreversible electroporation. Current value for focal treatment of prostate cancer].
    Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB;
    Urologe A; 2015 Jun; 54(6):854-62. PubMed ID: 26024649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irreversible Electroporation (IRE) for Prostate Cancer (PCa) Treatment: The State of the Art.
    Faiella E; Santucci D; Vertulli D; Vergantino E; Vaccarino F; Perillo G; Beomonte Zobel B; Grasso RF
    J Pers Med; 2024 Jan; 14(2):. PubMed ID: 38392571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
    Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M
    Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.
    Miñana López B; Andrés Boville G; Barbas Bernardos G; Ancizu Marckert X; Torres Roca M; Labairu Huerta L; Villacampa Aubá F; Ramón de Fata Chillón F; Sanz Ortega J; Abengózar Muela M; Gallardo Madueño G; Benito Boíllos A; Alcázar Peral A; Díez-Caballero Alonso F
    J Urol; 2023 Jan; 209(1):261-270. PubMed ID: 36073928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of clinical and mpMRI findings of irreversible electroporation therapy for the treatment of localized prostate cancer: Preliminary results.
    Güleryüz Kızıl P; Altan ŞA; Tarhan NÇ; Adsan Ö
    Turk J Urol; 2021 Jul; 47(4):299-304. PubMed ID: 35118956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
    Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
    Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.